Background and objective: Blood transfusion has been associated with adverse outcomes in certain conditions. This study investigates the prevalence and outcomes of red blood cell (RBC) transfusion in patients with acute pulmonary embolism (PE). Methods: Retrospective study of consecutive patients from 2000 to 2012 admitted to a tertiary hospital with a primary diagnosis of acute PE. Transfusion status during the hospital admission was ascertained. Mortality was tracked from a state-wide death database and analysed using multivariable modelling. Results: A total of 73 patients (5% of all patients admitted with PE) received RBC transfusion during their admission. These patients were significantly older, had more co-morbidities, worse haemodynamics, higher simplified pulmonary embolism severity index scores, and lower plasma sodium and haemoglobin (Hb) levels at admission. Unadjusted mortality for the transfused group was significantly higher at 30-day (19% vs 4%, P < 0.001) and 6-month (40% vs 10%, P < 0.001) followup. Multivariable modelling showed RBC transfusion to be a significant independent predictor of mortality at 30-day (odds ratio 3.06, 95% CI: 1.17-8.01, P = 0.02) and 6-month (hazard ratio (HR) 1.97, 95% CI: 1.12-3.46, P = 0.02). Sensitivity analysis confirmed that transfused patients had higher mortality than non-transfused patients in the subgroup of patients with Hb <100 g/L. Conclusion: RBC transfusion in patients hospitalized with acute PE is rare and appears to be associated with increased risk of short-and long-term mortality, independent of Hb level on admission. This finding underscores the need for future randomized controlled studies on the impact of RBC transfusion in the management of patients admitted with acute PE. [Correction added on 4 May 2018, after first online publication: the word 'serum' was changed to 'plasma' throughout the article where appropriate.]
INTRODUCTION
Anaemia is associated with higher morbidity and mortality in patients with acute and chronic cardiopulmonary diseases, including acute myocardial infarction, heart failure, pneumonia and COPD. [1] [2] [3] [4] Treating anaemia with red blood cell (RBC) transfusion after acute myocardial infarction, congestive heart failure and ischaemic stroke is controversial and has been linked with adverse outcomes. [5] [6] [7] [8] Acute pulmonary embolism (PE) is the third leading cause of cardiovascular death after coronary artery disease and stroke. 9 Anaemia as a predictor of mortality following acute PE has been rarely studied. Two studies suggested lower haemoglobin (Hb) levels were associated with increased mortality in acute PE 10, 11 ; however, the authors acknowledged the lack of data on RBC transfusion as an important limitation in their studies.
The aim of this study was to investigate the prevalence of RBC transfusion during admission and its relation with short-term (30-day) and long-term (6-month) mortality in a large cohort of patients hospitalized with acute PE.
METHODS

Study cohort
This was a retrospective cohort study based on a dedicated PE database of consecutive patients 
SUMMARY AT A GLANCE
This study is the first to identify blood transfusion as an independent predictor of mortality in pulmonary embolism. In our study, 5% of patients received blood transfusion. Mortality was significantly higher in this group of patients and multivariable modelling showed blood transfusion to be an independent predictor of mortality.
admitted with a primary confirmed diagnosis of acute PE between January 2000 and December 2012 to a tertiary-referral institution (Concord Hospital, Sydney, Australia). Outcomes of patients from this PE database have previously been published. 12, 13 The diagnosis of acute PE required for inclusion into the database is defined by: (i) a high clinical probability of PE; (ii) imaging studies consistent with the diagnosis (either a positive result on nuclear pulmonary ventilation/perfusion scintigraphy or computed tomography pulmonary angiogram); and (iii) the attending physician acknowledging the diagnosis in the medical records and commencing anticoagulation treatment.
Patients who presented with more than one episode of acute PE during the study period only had the initial presentation included in the analysis. Patients who are not residents of the local state (New South Wales) during their PE presentation were excluded from the study to minimize incomplete tracking of long-term outcomes. Patients were also excluded from the study if they did not have a plasma Hb level taken during admission.
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Concord Hospital Human Research Ethics Committee (CH62/612015-06). The Ethics Committee also granted a waiver of the usual requirement for consent of the individual to the use of their health information. All patients' data were de-identified and analysed anonymously.
Data sources
The PE database contains details of patient's admission history including haemodynamics (heart rate, blood pressure, oxygen saturation), co-morbidities, laboratory blood tests at admission (plasma sodium, Hb, creatinine, international normalized ratio) and medications on admission. Co-morbidities based on the International Classification of Diseases 10th revision coding were recorded. Each patient had their simplified pulmonary embolism severity index (sPESI) and Charlson Comorbidity Index (CCI) scores calculated from the extracted data.
14,15 Data on RBC transfusion was collected from the hospital Blood Bank Department database by cross-referencing and identifying patients who received RBC transfusion during their PE admission.
Study outcomes
The primary outcome of this study was all-cause mortality at 30-day and 6-month time-points, representing short-and long-term mortality following admission for acute PE, respectively. The assessment of mortality of patients in this database uses linkage to a state-wide death registry. 12, 13 All patients were followed up for a minimum of 6 months. The use of a state-wide death registry to obtain our primary outcome is advantageous as non-captured deaths during this period were estimated to be only 0.6% based on known migration rates. 16 
Statistical analysis
Patients were divided into two groups based on whether they received RBC transfusion at any time during the admission. All continuous variables were expressed as mean AE SD and categorical variables expressed as frequencies and percentages. Comparison between the two groups used unpaired t-test for continuous variables and chi-square test for categorical variables. Kaplan-Meier survival curves were used to compare unadjusted survival between the two groups. The prognostic significance of all collected variables was assessed using univariable regression analyses. Only significant variables (defined as P < 0.05) were then included in the multivariable regression analyses. To identify predictors of 30-day mortality, the binary logistic regression method was used, while Cox proportional hazards regression method was used to identify predictors of 6-month mortality. A two-tailed P value <0.05 was considered statistically significant. All analyses were performed using SPSS v22 (IBM, New York, NY, USA).
RESULTS
Baseline characteristics
There were 1426 patients admitted with a confirmed diagnosis of PE between 2000 and 2012. Of these patients, 50 were excluded from further analysis due to missing data on plasma Hb level during admission, leaving a final study cohort of 1376 patients. Table 1 shows the baseline characteristics of the study cohort. Patients who received RBC transfusion during their admission were older, had longer length of stay, more heart failure, malignancy, chronic renal disease and a significantly higher CCI; they also had worse haemodynamic profiles at admission including higher heart rates, lower systolic BP, lower oxyhaemoglobin saturation and higher sPESI scores. Furthermore, patients receiving RBC transfusion were more likely to have lower plasma sodium, estimated glomerular filtration rates, Hb and higher international normalized ratio (INR). Although the number of patients receiving thrombolysis were small, patients receiving RBC transfusion were more likely to have undergone thrombolysis. There were no differences in the use of aspirin, clopidogrel, warfarin, enoxaparin or direct oral anticoagulants between the two groups. In the subgroup of patients with malignancy, there was a significant difference between the transfused and non-transfused group in rates of haematological malignancy (36% vs 17%, P = 0.01), and no significant difference in rates of other malignancies (Table S1 in Supplementary Information). Table 2 shows the short-and long-term all-cause mortality of patients in each group. Unadjusted mortality was significantly higher in the patients receiving RBC transfusions at both 30-day (19% vs 4%, P < 0.001) and 6-month time-points (40% vs 10%, P < 0.001). Figure 1 shows the unadjusted Kaplan-Meier survival curves for both the transfused and non-transfused patients up to 6 months.
All-cause mortality
Prognostic impact of RBC transfusion and its interaction with plasma Hb level
Significant univariable predictors of 30-day mortality included age, stroke, heart failure, hyperlipidaemia, malignancy, chronic pulmonary disease, systolic BP, oxyhaemoglobin saturation, sPESI, day-1 plasma sodium, INR, Hb, and RBC transfusion (Table S2 in Supplementary Information). Multivariable modelling was then used to assess the prognostic impact of plasma Hb and RBC transfusion (Table 3) . To avoid overfitting of the models, the aggregate score sPESI (which incorporates age, heart failure, malignancy, chronic pulmonary disease, systolic BP and oxyhaemoglobin saturation) was used. RBC transfusion was found to be a significant independent predictor of 30-day mortality (odds ratio (OR) 3.06, 95% CI: 1.17-8.01, P = 0.02) after adjustment Significant univariable predictors of 6-month mortality included age, stroke, heart failure, hypertension, hyperlipidaemia, malignancy, heart rate, systolic BP, oxyhaemoglobin saturation, sPESI, day-1 plasma sodium, Hb, INR and RBC transfusion (Table S3 in Supplementary Information). Table 4 shows the multivariable modelling used to assess the prognostic impact of plasma Hb and RBC transfusion on 6-month mortality. RBC transfusion remained a significant independent predictor of long-term mortality after adjusting for other significant univariable predictors (HR 1.97, 95% CI: 1.12-3.46, P = 0.02), whereas plasma Hb became non-significant (HR 0.99, 95% CI: 0.98-1.00, P = 0.054). The adjusted survival curves comparing patients that received RBC transfusion and those that did not are shown in Figure 2 .
There was no dose effect associated with the number of RBC units transfused on either 1-month mortality (OR 0.92, 95% CI: 0.64-1.33, P = 0.66) or 6-month mortality (HR 0.78, 95% CI: 0.56-1.09, P = 0.15) on univariable analysis.
Sensitivity analysis
Given the significant differences in plasma Hb level on admission between the transfused and non-transfused groups, a sensitivity analysis was performed to assess the impact of RBC transfusion in the subgroup of patients with anaemia. For this analysis, a cut-off of plasma Hb ≤100 g/L was used, with all patients excluded if their admission plasma Hb was >100 g/L. This subgroup analysis consisted of 106 patients: 54 (51%) patients had transfusions and 52 (49%) did *Transfusion cohort of patients who received at least one unit of pack cell transfusion during admission. † Neurodegenerative disease includes dementia and Parkinson's disease. Conditions incorporated in the Charlson Comorbidity Index include myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, COPD, connective tissue disease, peptic ulcer disease, liver disease (mild vs. moderate to severe), diabetes (with or without organ damage), hemiplegia, moderate-to-severe renal disease, any tumour (within last 5 years), lymphoma, leukaemia, metastatic solid tumour and acquired immunodeficiency syndrome.
‡ Shock index = heart rate divided by systolic BP (index >0.7 signify hemodynamic compromise). ; RBC, red blood cell; SCR, plasma creatinine concentration (μmol/ L); and age is expressed in years; INR, international normalized ratio; sPESI, simplified pulmonary embolism severity (sPESI score incorporates age, history of malignancy, heart failure/chronic lung disease, heart rate ≥ 110 beats/min, systolic blood pressure <100 mm Hg and oxyhaemoglobin saturation < 90%). ‡ Transfusion cohort was patients who received at least one unit of pack cell transfusion during admission. Figure 1 Unadjusted Kaplan-Meier survival curve of patients that received RBC transfusion versus those that did not. The broken line shows the survival curve of patients that received RBC transfusions during their admission, while the unbroken line represents patients that did not receive RBC transfusions. There was a significant difference in survival between the groups at 1 month and 6 months (P < 0.001).
, Not transfused; , transfused.
not. The baseline characteristics of these patients are shown in Table S4 in Supplementary Information. Admission plasma Hb level was similar between the transfused and non-transfused groups (87 AE 10 vs 90 AE 16 g/L, respectively, P = 0.18). The transfused group had significantly higher unadjusted 6-month mortality compared to the non-transfused group (37% vs 10%, P = 0.001) ( Table S5 in Supplementary Information). RBC transfusion, sPESI, chronic pulmonary disease and malignancy were the only significant univariable predictors of 6-month mortality in this cohort. RBC transfusion was associated with a trend towards increased mortality (HR 2.81, 95% CI: 0.97-8.16, P = 0.06) after adjusting for sPESI in multivariable analysis (Tables S6,S7 in Supplementary Information).
DISCUSSION
To our knowledge, this is the first study to investigate outcomes following RBC transfusion in patients with acute PE. Although RBC transfusion is not commonly administered in patients with PE, our data suggests that transfusion is a significant independent predictor of both short-term and long-term mortality; furthermore, the prognostic impact of plasma Hb on admission loses significance when the presence of RBC transfusion is taken into account.
Jimenez et al. first demonstrated in a single-centre study of 764 patients that low plasma Hb levels on admission, categorized by quartiles, independently predicted 3-month mortality in acute PE. 10 This was later confirmed by Donze et al. in a large multicentre observational study involving 14 276 patients, where anaemia (defined as Hb <13 g/dL for men and < 12 g/dL for women) was independently associated with an increased 30-day mortality after acute PE. 11 In these studies, every 1 g/L decrease in admission Hb was associated with an 18% increase in 30-day mortality 11 and 16% increase in 3-month mortality. 10 However, both studies did not take into account whether patients received RBC transfusions, and the authors acknowledged this important limitation in their study design.
In the present study, approximately 5% of the study cohort received RBC transfusion during admission. These patients were older, had more co-morbidities, and worse haemodynamics at admission. Patients receiving RBC transfusion had significantly lower Hb compared to those that did not receive transfusion. This suggests that RBC transfusion was only reserved for patients with the most clinically severe cases of anaemia as well as those with significant comorbidities where anaemia may significantly worsen outcomes. Despite this, RBC transfusion remained a significant adverse independent predictor of both short-term and long-term all-cause mortality after adjusting for other significant univariable predictors. On the other hand, while admission plasma Hb was a INR, international normalized ratio; RBC, red blood cell; sPESI, simplified pulmonary embolism severity (sPESI score incorporates age, history of malignancy, heart failure/chronic lung disease, heart rate ≥ 110 beats/min, systolic blood pressure <100 mm Hg and oxyhaemoglobin saturation <90%). INR, international normalized ratio; RBC, red blood cell; sPESI, simplified pulmonary embolism severity (sPESI score incorporates age, history of malignancy, heart failure/chronic lung disease, heart rate ≥ 110 beats/min, systolic blood pressure <100 mm Hg and oxyhaemoglobin saturation < 90%). Figure 2 Adjusted survival curve of patients that received RBC transfusion versus those that did not. The broken line shows the survival curve of patients that received RBC transfusions during their admission, while the unbroken line represents patients that did not receive RBC transfusions. The groups were adjusted for stroke, hypertension, hyperlipidaemia, simplified pulmonary embolism severity index, haemoglobin level and international normalized ratio. There was a significant difference in survival between the groups at 6 months (P = 0.019).
, Not transfused;
, transfused.
significant predictor of unadjusted mortality in our study, its prognostic impact was lost once multivariable adjustment was performed. Our study suggests that RBC transfusion is a more powerful predictor of mortality in acute PE than the presence of anaemia on admission alone. The adverse impact of RBC transfusion has been well documented and includes risk of blood-borne infections, transfusion-related circulatory overload, acute lung injury and inducing a prothrombotic state. 17 These considerations continue to challenge clinicians to balance the risks and benefits of treating anaemia with transfusions, and have led to controversies on whether transfusion should be administered to anaemic patients in the absence of compelling clinical reasons, such as severe symptoms or haemodynamic instability. RBC transfusions have been associated with increased mortality and poor outcomes in patients with subarachnoid haemorrhage due to increased risk of thrombotic events. 7 Conversely, administering RBC transfusions to patients with ischaemic stroke did not worsen their prognosis, although the treatment was associated with longer duration of mechanical ventilation and length of stay in intensive care units. 8 In patients with congestive cardiac failure, lowering the Hb threshold for RBC transfusion has not led to lower mortality. 6 Perhaps the most controversial use of RBC transfusions has come from its use in patients with acute myocardial infarction, with a lack of consensus regarding its benefits on patient outcomes. 5, [18] [19] [20] Contemporary clinical guidelines generally recommend restrictive RBC transfusion practices in patients with anaemia. For example, the 2015 National Institute for Health and Care Excellence (NICE) guidelines on blood transfusion suggested transfusing at a Hb threshold of 70 g/L for patients without major haemorrhage, acute coronary syndrome, or chronic anaemia requiring regular transfusions; a Hb threshold of 80 g/L was suggested for transfusions in patients with acute coronary syndrome. 21 The rationale for transfusing patients with a lower Hb threshold is based on strong evidence from observational studies as well as a meta-analysis of randomized studies that did not show any significant increase in mortality in patients with a restrictive transfusion strategy. [22] [23] [24] The pathophysiological link between RBC transfusion and increased mortality in patients presenting with PE has not been explored until now. Beyond the additional risks of adverse transfusion reactions, there are several possible mechanisms relating to changes in stored blood that may be of relevance. First, using stored RBC leads to a prothrombotic state via several physiological pathways, including increased blood viscosity, release of free Hb (a potent nitric oxide scavenger) causing reduced nitric oxide concentrations, subsequent vasoconstriction, and alterations in platelet activation and aggregation. [25] [26] [27] [28] Given that patients with established PE already have risk factors predisposing to their prothrombotic state, this mechanism is highly plausible. Clinicians may also be hesitant to offer full anticoagulation to patients with anaemia if there is suspicion of underlying bleeding. Second, storage of blood leads to significant decreases in 2,3-diphosphoglycerate acid and adenosine triphosphate concentrations, which reduces the RBC capacity to off-load oxygen at tissue sites. 29 Since patients with acute PE already possess reduced cardiorespiratory reserves, placing additional preload stress on the heart through transfusion without providing additional oxygenation may be highly detrimental. Further research is needed to confirm these potential deleterious mechanisms of transfusion in PE patients.
Our study has several limitations. First, it is a singlecentre study thus susceptible to sampling bias. Whilst our findings remain robust due to a large cohort, this should be confirmed in a multicentre study. Second, this was a retrospective study; thus not all patients' variables can be accounted for. As a consequence, we were unable to adjust for all confounders. In particular, we did not possess data on clinically significant bleeding in our patients which can adversely impact outcomes in PE. 30 Third, the rate of RBC transfusion in our cohort is low (~5%), which may have led to overestimation of its effect on outcomes, and the results should be considered hypothesis-generating until confirmation in larger multicentre studies. Finally, we were unable to explore the impact of other methods of managing anaemia in our PE cohort, such as iron infusion or erythropoietin supplementation.
In summary, in this large contemporary cohort of patients presenting with acute PE, RBC transfusion is rare and independently associated with increased mortality at 30-day and at 6-month. Our findings raise concerns about the safety of RBC transfusion in these patients and underscore the need for further multicentre observational and randomized controlled studies to definitively address the impact of this treatment. 
